Matt Miksic
Stock Analyst at Barclays
(3.79)
# 686
Out of 4,944 analysts
291
Total ratings
60.17%
Success rate
4.08%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Maintains: Overweight | $53 → $51 | $11.11 | +359.25% | 7 | Aug 8, 2025 | |
| BAX Baxter International | Maintains: Overweight | $41 → $36 | $23.98 | +50.13% | 22 | Aug 4, 2025 | |
| ATEC Alphatec Holdings | Maintains: Overweight | $21 → $22 | $15.72 | +39.95% | 3 | Aug 4, 2025 | |
| INMD InMode | Maintains: Overweight | $24 → $21 | $14.22 | +47.68% | 14 | Jul 30, 2025 | |
| DXCM DexCom | Maintains: Equal-Weight | $93 → $98 | $80.17 | +22.24% | 7 | Jul 30, 2025 | |
| EW Edwards Lifesciences | Maintains: Overweight | $90 → $95 | $76.93 | +23.49% | 29 | Jul 25, 2025 | |
| BSX Boston Scientific | Maintains: Overweight | $125 → $133 | $102.64 | +29.58% | 18 | Jul 24, 2025 | |
| ZIMV ZimVie | Upgrades: Equal-Weight | $9 → $19 | $18.86 | +0.74% | 8 | Jul 22, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $165 → $176 | $172.78 | +1.86% | 13 | Jul 17, 2025 | |
| BLCO Bausch + Lomb | Maintains: Equal-Weight | $19 → $16 | $13.77 | +16.19% | 5 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $241 | $194.96 | +23.62% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $56 → $55 | $50.64 | +8.61% | 7 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $12 | $2.72 | +341.18% | 2 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $234 → $266 | $309.63 | -14.09% | 8 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $684 → $635 | $478.19 | +32.79% | 7 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $158 → $159 | $131.02 | +21.36% | 29 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $103 | $61.87 | +66.48% | 15 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $118 → $112 | $101.82 | +10.00% | 7 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $418 → $443 | $376.61 | +17.63% | 23 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $3.66 | +501.09% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $109 | $92.08 | +18.38% | 21 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $96 | $86.03 | +11.59% | 9 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $67.52 | +48.10% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $140.49 | +197.53% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $14.86 | +88.43% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $13.05 | +413.41% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $480 | $10.35 | +4,537.68% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $13.77 | +531.81% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $4.89 | +411.25% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $7.23 | +24.48% | 1 | Dec 12, 2016 |
Tandem Diabetes Care
Aug 8, 2025
Maintains: Overweight
Price Target: $53 → $51
Current: $11.11
Upside: +359.25%
Baxter International
Aug 4, 2025
Maintains: Overweight
Price Target: $41 → $36
Current: $23.98
Upside: +50.13%
Alphatec Holdings
Aug 4, 2025
Maintains: Overweight
Price Target: $21 → $22
Current: $15.72
Upside: +39.95%
InMode
Jul 30, 2025
Maintains: Overweight
Price Target: $24 → $21
Current: $14.22
Upside: +47.68%
DexCom
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $93 → $98
Current: $80.17
Upside: +22.24%
Edwards Lifesciences
Jul 25, 2025
Maintains: Overweight
Price Target: $90 → $95
Current: $76.93
Upside: +23.49%
Boston Scientific
Jul 24, 2025
Maintains: Overweight
Price Target: $125 → $133
Current: $102.64
Upside: +29.58%
ZimVie
Jul 22, 2025
Upgrades: Equal-Weight
Price Target: $9 → $19
Current: $18.86
Upside: +0.74%
Johnson & Johnson
Jul 17, 2025
Maintains: Equal-Weight
Price Target: $165 → $176
Current: $172.78
Upside: +1.86%
Bausch + Lomb
Jun 9, 2025
Maintains: Equal-Weight
Price Target: $19 → $16
Current: $13.77
Upside: +16.19%
Jun 3, 2025
Maintains: Overweight
Price Target: $261 → $241
Current: $194.96
Upside: +23.62%
May 8, 2025
Maintains: Equal-Weight
Price Target: $56 → $55
Current: $50.64
Upside: +8.61%
May 5, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $2.72
Upside: +341.18%
Apr 30, 2025
Maintains: Equal-Weight
Price Target: $234 → $266
Current: $309.63
Upside: -14.09%
Apr 24, 2025
Maintains: Overweight
Price Target: $684 → $635
Current: $478.19
Upside: +32.79%
Apr 17, 2025
Maintains: Overweight
Price Target: $158 → $159
Current: $131.02
Upside: +21.36%
Feb 24, 2025
Maintains: Overweight
Price Target: $100 → $103
Current: $61.87
Upside: +66.48%
Feb 10, 2025
Maintains: Underweight
Price Target: $118 → $112
Current: $101.82
Upside: +10.00%
Feb 10, 2025
Maintains: Overweight
Price Target: $418 → $443
Current: $376.61
Upside: +17.63%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $3.66
Upside: +501.09%
Nov 26, 2024
Maintains: Overweight
Price Target: $105 → $109
Current: $92.08
Upside: +18.38%
May 13, 2022
Assumes: Outperform
Price Target: $96
Current: $86.03
Upside: +11.59%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $67.52
Upside: +48.10%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $140.49
Upside: +197.53%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $14.86
Upside: +88.43%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $13.05
Upside: +413.41%
Jan 7, 2022
Initiates: Outperform
Price Target: $480
Current: $10.35
Upside: +4,537.68%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $13.77
Upside: +531.81%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $4.89
Upside: +411.25%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $7.23
Upside: +24.48%